BR112017026272A2 - ?composto, composição farmacêutica, método para o tratamento de uma desordem relacionada a receptor m1 muscarínico e uso do composto? - Google Patents

?composto, composição farmacêutica, método para o tratamento de uma desordem relacionada a receptor m1 muscarínico e uso do composto?

Info

Publication number
BR112017026272A2
BR112017026272A2 BR112017026272A BR112017026272A BR112017026272A2 BR 112017026272 A2 BR112017026272 A2 BR 112017026272A2 BR 112017026272 A BR112017026272 A BR 112017026272A BR 112017026272 A BR112017026272 A BR 112017026272A BR 112017026272 A2 BR112017026272 A2 BR 112017026272A2
Authority
BR
Brazil
Prior art keywords
compound
muscarinic
receptor
treating
pharmaceutical composition
Prior art date
Application number
BR112017026272A
Other languages
English (en)
Other versions
BR112017026272B1 (pt
Inventor
Rasheed Mohammed Abdul
Karbhari Shinde Anil
Nirogi Ramakrishna
Reddy Gagginapally Shankar
Jasti Venkateswarlu
Original Assignee
Suven Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suven Life Sciences Ltd filed Critical Suven Life Sciences Ltd
Publication of BR112017026272A2 publication Critical patent/BR112017026272A2/pt
Publication of BR112017026272B1 publication Critical patent/BR112017026272B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
    • C07D279/16—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Liquid Crystal Display Device Control (AREA)
  • Arrangement And Driving Of Transmission Devices (AREA)
  • Electrophonic Musical Instruments (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

a presente invenção se refere a um composto tendo a fórmula (i), ou estereoisômeros e sais farmaceuticamente aceitáveis como moduladores alostéricos positivos de receptor m1 muscarínico. a presente invenção também se refere a métodos de preparar os referidos compostos e composições farmacêuticas que compreendem os referidos compostos. os compostos da presente invenção são úteis no tratamento de várias desordens que são relacionadas a receptor m1 muscarínico.
BR112017026272-0A 2015-06-08 2016-06-08 Composto e composição farmacêutica BR112017026272B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN2851/CHE/2015 2015-06-08
IN2851CH2015 2015-06-08
PCT/IB2016/000771 WO2016198937A1 (en) 2015-06-08 2016-06-08 Muscarinic m1 receptor positive allosteric modulators

Publications (2)

Publication Number Publication Date
BR112017026272A2 true BR112017026272A2 (pt) 2018-09-11
BR112017026272B1 BR112017026272B1 (pt) 2023-04-11

Family

ID=56411822

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017026272-0A BR112017026272B1 (pt) 2015-06-08 2016-06-08 Composto e composição farmacêutica

Country Status (29)

Country Link
US (1) US10308620B2 (pt)
EP (1) EP3303331B1 (pt)
JP (1) JP6466602B2 (pt)
KR (1) KR102052058B1 (pt)
CN (1) CN107922400B (pt)
AU (1) AU2016276139B2 (pt)
BR (1) BR112017026272B1 (pt)
CA (1) CA2987843C (pt)
CY (1) CY1121693T1 (pt)
DK (1) DK3303331T3 (pt)
EA (1) EA032602B1 (pt)
ES (1) ES2719626T3 (pt)
HK (1) HK1247919A1 (pt)
HR (1) HRP20190624T1 (pt)
HU (1) HUE044902T2 (pt)
IL (1) IL255994B (pt)
LT (1) LT3303331T (pt)
MA (1) MA43913B1 (pt)
MD (1) MD3303331T2 (pt)
ME (1) ME03379B (pt)
MX (1) MX2017015961A (pt)
NZ (1) NZ737892A (pt)
PL (1) PL3303331T3 (pt)
PT (1) PT3303331T (pt)
RS (1) RS58665B1 (pt)
SI (1) SI3303331T1 (pt)
TR (1) TR201904639T4 (pt)
WO (1) WO2016198937A1 (pt)
ZA (1) ZA201708108B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3076757C (en) * 2017-10-18 2022-10-11 Suven Life Sciences Limited Heteroaryl compounds as muscarinic m1 receptor positive allosteric modulators
JP7110338B2 (ja) * 2017-10-27 2022-08-01 スヴェン・ライフ・サイエンシーズ・リミテッド ムスカリンｍ１受容体陽性アロステリックモジュレーターである多環式アミド類
WO2020206410A1 (en) * 2019-04-04 2020-10-08 University Of Maryland, Baltimore Methods of using muscarinic antagonists in the treatment of depression
KR102285472B1 (ko) 2019-06-14 2021-08-03 엘지전자 주식회사 음향의 이퀄라이징 방법과, 이를 구현하는 로봇 및 ai 서버
CN110606827B (zh) * 2019-09-26 2023-03-14 西安凯立新材料股份有限公司 一步法合成甲氨基吡啶类化合物的方法
WO2023114224A1 (en) 2021-12-13 2023-06-22 Sage Therapeutics, Inc. Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1183847A (en) 1981-10-01 1985-03-12 Georges Van Daele N-(3-hydroxy-4-piperidinyl)benzamide derivatives
AU2006322045A1 (en) 2005-12-05 2007-06-14 Merck & Co., Inc. Quinolone M1 receptor positive allosteric modulators
US8883850B2 (en) 2010-05-28 2014-11-11 Merck Sharp & Dohme Corp. Naphthalene carboxamide M1 receptor positive allosteric modulators
JP2014076948A (ja) 2011-02-09 2014-05-01 Astellas Pharma Inc イソキノリンアミド誘導体
US9403802B2 (en) * 2012-03-02 2016-08-02 Takeda Pharmaceutical Company Limited Heterocyclic compound and use therefor
TW201512197A (zh) 2013-08-30 2015-04-01 Hoffmann La Roche 吡咯并吡啶或吡唑并吡啶衍生物
GB201317363D0 (en) 2013-10-01 2013-11-13 Eisai Ltd Novel compounds
US9708278B2 (en) * 2013-11-27 2017-07-18 Vanderbilt University Substituted 4-benzyl-3,4-dihydro-2H-benzo[B][1,4]oxazine-2-carboxamide analogs as positive allosteric modulators of muscarinic acetycholine receptor M1
GB201409044D0 (en) * 2014-05-21 2014-07-02 Ucl Business Plc New compounds

Also Published As

Publication number Publication date
NZ737892A (en) 2018-09-28
EP3303331A1 (en) 2018-04-11
KR20180016528A (ko) 2018-02-14
KR102052058B1 (ko) 2019-12-04
HRP20190624T1 (hr) 2019-05-31
MA43913A (fr) 2018-04-11
EA032602B1 (ru) 2019-06-28
MA43913B1 (fr) 2019-05-31
ZA201708108B (en) 2018-11-28
AU2016276139A1 (en) 2018-01-04
PL3303331T3 (pl) 2019-06-28
JP6466602B2 (ja) 2019-02-06
RS58665B1 (sr) 2019-06-28
PT3303331T (pt) 2019-04-30
DK3303331T3 (en) 2019-04-23
US10308620B2 (en) 2019-06-04
EP3303331B1 (en) 2019-02-27
HUE044902T2 (hu) 2019-11-28
CN107922400A (zh) 2018-04-17
ES2719626T3 (es) 2019-07-11
CA2987843C (en) 2020-07-14
CY1121693T1 (el) 2020-07-31
BR112017026272B1 (pt) 2023-04-11
ME03379B (me) 2020-01-20
IL255994A (en) 2018-01-31
WO2016198937A1 (en) 2016-12-15
LT3303331T (lt) 2019-04-25
EA201792594A1 (ru) 2018-06-29
HK1247919A1 (zh) 2018-10-05
SI3303331T1 (sl) 2019-05-31
MD3303331T2 (ro) 2019-05-31
JP2018521024A (ja) 2018-08-02
US20180155302A1 (en) 2018-06-07
MX2017015961A (es) 2018-07-06
TR201904639T4 (tr) 2019-05-21
IL255994B (en) 2018-04-30
CN107922400B (zh) 2021-05-11
AU2016276139B2 (en) 2018-07-19
CA2987843A1 (en) 2016-12-15

Similar Documents

Publication Publication Date Title
BR112017026272A2 (pt) ?composto, composição farmacêutica, método para o tratamento de uma desordem relacionada a receptor m1 muscarínico e uso do composto?
BR112018015273A2 (pt) derivados de benzimidazol como moduladores de ror-gama
BR112019006712A2 (pt) composto, composição farmacêutica, composição para uso no tratamento de uma doença, elemento implantável, e, dispositivo.
BR112019003932A2 (pt) composto, composição farmacêutica, combinação, método de tratamento de uma doença ou desordem e uso do composto
BR112017007662A2 (pt) composto, composição farmacêutica, processo de elaboração de uma composição farmacêutica, método de tratamento de distúrbio ou doença relativa a er, kit de tratamento e uso de composto
BR112016016844A2 (pt) Compostos heterocíclicos
BR112017004448A2 (pt) uso de agente de reforço de receptor gabaa na preparação de medicamento sedativo e anestésico
BR112018070123A2 (pt) oxiesterós e métodos de uso dos mesmos
BR112016010383A2 (pt) compostos de pyy seletivos e usos dos mesmos
BR112018004719A2 (pt) composto de fluoroindola, composição farmacêutica, método para o tratamento de uma desordem relacionada a receptor muscarínico m1 e uso do composto
BR112014022780A2 (pt) composto modulador de receptor de fígado x, composição farmacêutica que o compreende e seu uso
BR112016030733A2 (pt) Derivados de indano e indolina e uso dos mesmos como ativadores de guanilato ciclase solúveis
BR112015030385A8 (pt) composto, composto para uso e composição farmacêutica
BR112016028845A2 (pt) composto, composição farmacêutica e uso de um composto
EA202091262A1 (ru) Пиперидиновые модуляторы рецепторов cxcr7
EA202191513A1 (ru) Снижение вязкости фармацевтических составов
BR112018006545A2 (pt) ?composto, composição farmacêutica, combinação, uso de um composto, e, método para tratamento de uma doença ou condição?
BR112014001083B8 (pt) Composto, processo para a preparação de um composto, composição farmacêutica, uso da composiçâo farmacêutica e uso do composto
BR112017017275A2 (pt) composto, composição farmacêutica, método para o tratamento e uso do composto
EA201791600A1 (ru) Производные гидроксиалкилпиперазина в качестве модуляторов cxcr3 рецептора
BR112017002852A2 (pt) compostos de azetidiniloxifenilpirrolidina
BR112016020556A8 (pt) compostos, composição farmacêutica, método de modulação da atividade do receptor de grelina, método para o tratamento de uma doença e usos de um composto
BR112016013974A8 (pt) composto, composição farmacêutica e uso de um composto.
BR112018073419A2 (pt) combinação, uso da combinação, método para o tratamento, composto, método para o tratamento de doença de alzheimer e composição farmacêutica
BR112018073396A2 (pt) combinação de antagonistas, uso de uma combinação, método para o tratamento de desordens cognitivas, composto, método para o tratamento de doença de alzheimer e composição farmacêutica

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/06/2016, OBSERVADAS AS CONDICOES LEGAIS